Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocuphire Pharma, Inc.

1.17
0.0000
Volume:- -
Turnover:- -
Market Cap:30.65M
PE:-1.97
High:1.17
Open:1.17
Low:1.17
Close:1.17
52wk High:3.40
52wk Low:1.15
Shares:26.20M
Float Shares:24.52M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5951
EPS(LYR):-0.4625
ROE:-36.01%
ROA:-21.35%
PB:0.75
PE(LYR):-2.53

Loading ...

Ocuphire Pharma Acquires Opus Genetics

MT Newswires Live
·
Oct 26, 2024

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

PR Newswire
·
Oct 26, 2024

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

TipRanks
·
Oct 24, 2024

Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Oct 24, 2024

Ocuphire Pharma rating placed under review at H.C. Wainwright

TIPRANKS
·
Oct 23, 2024

BRIEF-Ocuphire Pharma announces acquisition of Opus Genetics

Reuters
·
Oct 23, 2024

Ocuphire Pharma trading resumes

TIPRANKS
·
Oct 23, 2024

Ocuphire Pharma trading halted, news pending

TIPRANKS
·
Oct 23, 2024

Ocuphire Pharma Announces Acquisition of Opus Genetics

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Inc - Stockholders to Own 58%, Opus Genetics Stockholders 42% of Combined Co

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Inc - Combined Company to Be Renamed Opus Genetics, Trading as 'Ird'

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Inc - Lynx-2 Phase 3 Trial on Track for Top-Line Data in Q1 2025

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Inc - George Magrath to Continue as CEO of Combined Company

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Inc - Projected Cash Runway Extended Into 2026

THOMSON REUTERS
·
Oct 23, 2024

Ocuphire Pharma Announces Acquisition of Opus Genetics

GlobeNewswire
·
Oct 23, 2024

BRIEF-Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%

Reuters
·
Sep 30, 2024

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

THOMSON REUTERS
·
Sep 30, 2024

Ocuphire Pharma Inc: Phentolamine Ophthalmic Solution 0.75% Exhibited a Favorable Safety Profile

THOMSON REUTERS
·
Sep 30, 2024

Ocuphire Pharma Inc: Vega-3 Phase 3 Clinical Trial Top-Line Data Are Expected in First Half of 2025

THOMSON REUTERS
·
Sep 30, 2024